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Vav2, like all Dbl family proteins, possesses tandem Dbl homology (DH) and pleckstrin homology (PH)
domains and functions as a guanine nucleotide exchange factor for Rho family GTPases. Whereas the PH
domain is a critical positive regulator of DH domain function for a majority of Dbl family proteins, the PH
domains of the related Vav and Vav3 proteins are dispensable for DH domain activity. Instead, Vav proteins
contain a cysteine-rich domain (CRD) critical for DH domain function. We evaluated the contribution of the
PH domain and the CRD to Vav2 guanine nucleotide exchange, signaling, and transforming activity. Unex-
pectedly, we found that mutations of the PH domain impaired Vav2 signaling, transforming activity, and
membrane association. However, these mutations do not influence exchange activity on Rac and only slightly
affect exchange on RhoA and Cdc42. We also found that the CRD was critical for the exchange activity in vitro
and contributed to Vav2 membrane localization. Finally, we found that phosphoinositol 3-kinase activation
synergistically enhanced Vav2 transforming and signaling activity by stimulating exchange activity but not
membrane association. In conclusion, the PH domain and CRD are mechanistically distinct, positive modu-
lators of Vav2 DH domain function in vivo.
Rho family proteins are members of the Ras superfamily of
small GTPases. Currently, 18 mammalian Rho family proteins
have been identified, with Rac1, Cdc42, and RhoA being the
best characterized (37, 45). Rho family GTPases are guanine
nucleotide binding proteins that function as molecular switches
that cycle between active GTP-bound and inactive GDP-bound
states. Dbl family proteins serve as guanine nucleotide ex-
change factors (GEFs), which accelerate the intrinsic GDP/
GTP exchange activity of Rho GTPases to cause formation
of the active GTP-bound protein (8, 39). The activated Rho
GTPases then interact with a wide spectrum of downstream
effector proteins to mediate cellular activities that include reg-
ulation of actin cytoskeletal organization, gene expression, and
cellular proliferation (3). A second class of regulatory proteins,
Rho family-specific GTPase-activating proteins, stimulate in-
trinsic GTPase activity to return these small GTPases to their
inactive GDP-bound state and to terminate downstream sig-
naling (37).
Vav proteins (Vav, Vav2, and Vav3) are mammalian mem-
bers of the Dbl family of proteins (7). All Vav proteins have
similar structural organizations. Like all Dbl family proteins,
Vav proteins possess a Dbl homology (DH) domain followed
by a COOH-terminal pleckstrin homology (PH) domain (8,
39). Previous studies indicate that the DH domain interacts
directly with Rho family GTPases to catalyze GDP release (8,
39). The Vav DH domains exhibit broad GTPase specificity
and serve as GEFs for multiple Rho GTPases (RhoA, RhoG,
Rac1, and Cdc42), although different studies have reached
contrasting conclusions regarding the specific GTPases tar-
geted by Vav (1, 12, 17, 23, 28, 35, 43).
The invariant topography of DH and PH domains (DH/PH
domain) found in all Dbl family proteins suggests a critical role
for the PH domain in regulation of DH domain function.
Extensive structure-function analyses of the DH/PH domains
of various Dbl family proteins suggest that the PH domain may
serve two distinct functions to modulate DH domain activity
(8, 39). First, the PH domain may act as a positive modulator
of the intrinsic catalytic activity of the DH domain. For exam-
ple, a comparison of the catalytic activities of the DH and
DH/PH domains derived from several Dbl family proteins
(e.g., Dbl, Trio, and Dbs) showed that the GEF activity exhib-
ited by a PH-containing protein was up to 100-fold greater than
that measured for the DH domain alone in vitro (24, 34, 44).
Second, it may serve a membrane-targeting function and
regulate DH domain interaction with its membrane-bound
GTPase substrates. For example, the loss of function caused by
mutation of the PH domains of Lfc and Dbs could be reversed
by addition of a plasma membrane targeting sequence (40, 41).
In contrast to what has been observed for many Dbl family
proteins, the PH domains of Vav proteins appear to serve as
negative regulators of DH domain function and no role in
membrane targeting has been described. Han and colleagues
determined that the PH domain of Vav serves as a negative
regulator of DH domain GEF activity in vitro (18). This neg-
ative regulatory function is promoted by phosphatidylinositol
4,5-phosphate (PIP2), a substrate of phosphatidylinositol 3-ki-
nase (PI3K), and is antagonized by the PI3K product, phos-
phatidylinositol 3,4,5-phosphate (PIP3). Hence, PI3K activa-
tion is proposed to facilitate the activation of Vav. Consistent
with a negative regulatory function for the PH domain, Ma et
al. determined that a variant of Vav with its PH domain de-
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leted was activated constitutively in vivo (26). In evaluations of
PH domain function in NH2-terminally truncated and consti-
tutively activated versions of Vav proteins, mutation of the PH
domains of Vav and Vav3 did not cause significant alteration in
GEF activity in vitro or growth and/or morphological trans-
forming activity in vivo, suggesting that the PH domain is not
a critical regulator of Vav DH domain function (18, 28). Since
the role of the PH domain in Vav2 function has not been
addressed, it has not been previously established whether the
PH domains of Vav family proteins exhibit similar or distinct
functions.
Vav proteins also contain additional protein-protein or
protein-lipid interaction domains that flank the DH/PH do-
mains. A calponin homology domain and an acidic amino
acid-rich domain positioned NH2 terminal to the DH and
PH domains serve negative regulatory roles in Vav function
(7). Tyrosine phosphorylation of the NH2-terminal region
relieves this negative regulatory function. Hence, mutant
versions of all three Vav proteins with the NH2 termini
deleted are activated constitutively in a phosphorylation-
independent fashion and exhibit potent transforming activ-
ity (2, 20). COOH terminal to the PH domain are a cysteine-
rich domain (CRD) and an Src homology 2 (SH2) domain
that is flanked by two SH3 domains. The role of the SH
domains is to facilitate the phosphorylation of Vav (7).
Consistent with this role, the SH domains are dispensable
for the transforming activities of the NH2-terminally trun-
cated and transforming versions of Vav (35). In contrast,
mutational analyses determined that the CRD is critical for
the growth and/or morphological transforming activity of
Vav and Vav3 (11, 28). While the precise role of the CRD
in Vav function is not known, the impaired GEF activity in
vitro of a Vav3 CRD mutant, coupled with the capacity of
the isolated Vav3 CRD to bind to RhoA in vitro, argues that
the CRD may facilitate DH domain interaction with its
GTPase substrates (28). Thus, the CRD may substitute func-
tionally for the PH domain and hence render the PH domain
dispensable for Vav function. Whether the CRD can also
regulate Vav association with membranes has not been de-
termined.
In light of the incomplete or conflicting observations regard-
ing the role of the PH domain and CRD in Vav function, we
have evaluated the biological and biochemical contributions of
the PH domain and the CRD to Vav2 catalytic activity in vitro
and signaling and transforming activity in vivo. In contrast to
previous observations with Vav and Vav3, we found that an
intact PH domain is not required for the catalytic activity of the
DH domain in vitro but is required for complete biological and
catalytic activity of Vav2 in vivo and facilitates Vav2 associa-
tion with membranes. Similarly, mutation of the CRD also
impaired Vav2 signaling and transformation, in part, by im-
pairing the intrinsic catalytic activity of the DH domain. Fi-
nally, we found that PI3K activation enhanced the signaling
and transforming activity of Vav2; this enhancement involves
the PH domain but does not promote Vav2 association with
membranes. Taken together, our observations suggest the PH
domain and the CRD are both essential for complete Vav2
activity but that they serve distinct functions in regulating DH
domain activity.
MATERIALS AND METHODS
Molecular constructs. The pCGN-hygro mammalian expression vector regulates
the expression of introduced cDNA sequences from a cytomegalovirus promoter,
encodes hygromycin resistance, and introduces an NH2-terminal hemagglutinin
(HA) epitope tag into the encoded protein (14). Human Vav2 truncation mutants
were generated by PCR-mediated approaches using wild-type full-length human-
Vav2 cDNA (pCMV5-Vav2; a generous gift from Dan Broek) as the template. A 5
primer containing a BamHI site and sequences encoding eight Vav2 NH2-terminal
residues corresponding to residues 192 to 200 was used in conjunction with a 3
primer containing a BamHI restriction site and sequences encoding eight Vav2
COOH-terminal residues corresponding to residues 845 to 851 to generate a 2-kb
fragment encoding the sequence from the DH domain to the end of the protein.
Three additional 3 primers containing eight Vav2 COOH-terminal residues corre-
sponding to residues 565 to 573, 510 to 518, or 368 to 377 were used to generate a
1.7-kb fragment encoding the DH and PH domains and the CRD (residues 192 to
573 [Vav2-DPC]), a 1.2-kb fragment encoding the DH and PH domains (Vav2-DP),
and a 0.7-kb fragment encoding the DH domain (Vav2-D), respectively. All con-
structs were digested with BamHI and ligated into the BamHI site of pCGN-hygro
in frame with the HA epitope tag at the NH2 terminus. cDNA sequences encoding
missense mutations in the PH domain (K407A and W503L) or the CRD (K533A,
K538A, K563A, and V568E) of Vav2-DPC were introduced with the Quickchange
site-directed mutagenesis kit (Stratagene) in accordance with the manufacturer’s
protocol. All constructs were sequenced in their entirety to eliminate the possibility
of extra mutations.
Cell culture and transformation assay. NIH 3T3 mouse fibroblasts were cul-
tured in Dulbecco’s modified Eagle’s medium supplemented with 10% calf
serum. DNA transfections for transformation assays were performed by using the
calcium phosphate precipitation method as described previously (9). For each
assay, the cognate empty vector was used as a control. The transfected cultures
were maintained in culture media for 14 days, fixed, and stained with crystal
violet (0.5%), and the number of foci of transformed cells was then quantitated.
NIH 3T3 cells stably expressing the Vav2 mutants were established by transfec-
tion of pCGN-vav2 constructs and isolation of drug-resistant colonies after
growth in medium supplemented with hygromycin (400 g/l). Multiple drug-
resistant colonies (100) were pooled together to establish stable cell lines for
use in the various assays described.
Transient expression reporter gene assays. NIH 3T3 cells were transfected by
Lipofectamine Plus according to the manufacturer’s protocol. Forty-eight hours
posttransfection, cells were starved for 12 to 14 h with Dulbecco’s modified
Eagle’s medium supplemented with 0.5% bovine calf serum. Analyses of the cell
lysates of the transiently transfected NIH 3T3 cells were performed using en-
hanced chemiluminescence reagents and a Monolight 2010 luminometer (Ana-
lytical Luminescence). The (SREm)2 reporter plasmid contains a luciferase gene
whose expression is under the control of a serum response factor (SRF)-respon-
sive promoter as has been described previously (38). All assays were performed
at least in triplicate.
Guanine nucleotide exchange assays. cDNA fragments encoding either human
Vav2-DPC (residues 192 to 573) or the Vav2 PH domain (K407A) and CRD
(K533A, K538A, K563A, and V568E) mutants were generated by PCR and
inserted into the NcoI/XhoI sites of bacterial expression vector pET-28a (Nova-
gen). The bacterial expression constructs were transformed into Escherichia coli
strain BL21 (DE3), and protein expression was induced with 0.5 mM IPTG
(isopropyl--D-thiogalactopyranoside) at 22°C. The recombinant proteins were
His6 tagged at their COOH termini and were purified from bacterial lysate on a
nickel-nitrilotriacetic acid agarose column (Qiagen). Bacterially expressed glu-
tathione S-transferase (GST)-RhoA(F25N), GST-Rac1(WT), and GST-
Cdc42(WT) proteins were kindly provided by J. Sondek.
Fluorescence spectroscopy analysis of N-methylanthraniloyl (mant)–GDP in-
corporation into GDP-preloaded Rac1, Cdc42, and RhoA was carried out with
a Perkin-Elmer LS 50 B spectrometer at 20°C as described previously (1).
Exchange reaction mixtures containing 20 mM Tris, pH 7.5, 50 mM NaCl, 10%
glycerol, 400 nM mant-GDP (Biomol), and 2 M GTPase were prepared and
allowed to equilibrate with continuous stirring. After equilibration, each Vav2
polypeptide was added to 100 nM, and the relative mant fluorescence (excitation
 [ex]  360 nm; emission  [em]  440 nm) was monitored. All experiments
were performed in duplicate.
RESULTS
Vav2 transforming and signaling activity requires an intact
PH domain. An intact PH domain is critical for the transform-
ing activity of some Dbl family proteins by promoting DH
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domain catalytic function and/or by facilitating its association
with the plasma membrane (8). Surprisingly, mutational anal-
yses suggest that the PH domains of Vav family proteins serve
as negative regulators of DH domain function and hence are
dispensable for transforming activity (18, 26, 28). Instead, Vav
and Vav3 biological activity has been found to require an intact
CRD adjacent to the PH domain (11, 28). Therefore, in the
present study, we assessed whether the PH domain is dispens-
able and whether the CRD may serve analogous functions as
an important regulator of DH domain function and as a reg-
ulator of membrane association.
We determined previously that NH2-terminal deletion of all
sequences upstream of the DH domain of Vav2 (amino acids
1 to 191) results in a constitutively activated, highly transform-
ing Vav2 mutant (1). In the present study, we determined that
the COOH-terminal SH3-SH2-SH3 domain sequence is also
dispensable for Vav2 transforming and signaling activity (Fig.
1 and 2). Thus, as has been reported for Vav (35), the fragment
of Vav2 that contains the DH, PH, and CRD regions alone
(designated Vav2-DPC) defines a minimal functional, trans-
forming unit of Vav2. Therefore, we introduced mutations into
an HA epitope-tagged version of Vav2-DPC to evaluate the
role of the PH domain and CRD in Vav2 transforming activity.
We introduced two missense mutations in the PH domain of
FIG. 1. Primary structure and protein expression levels of the human Vav2 truncation and point mutants. (A) Schematic structure of full-length
human Vav2, NH2-terminal and COOH-terminal truncation mutants, and PH domain and CRD point mutants. Horizontal lines below full-length
Vav2 show the predicted translational product of each truncation or point mutant initiated at the indicated amino acid. NH2-terminally truncated
Vav2 (1-191) is a strongly transforming variant of Vav2, and further COOH-terminal truncation to generate the Vav2-DPC fragment (DPC) did
not reduce this activity. Therefore, to avoid potential complications in interpretation, all PH and CRD point mutants were generated in the
background of the highly transforming Vav2-DPC fragment. Vertical lines, mutations in the PH domain (K407A and W503L) and the CRD
(K533A, K538A, K563A, and V568E). Truncation mutants containing the DH and PH domains (DP) or DH domain (D) were also generated. The
1-191 and wild-type and mutant Vav2-DPC, -DP, and -D sequences were fused in frame to an HA epitope tag at the NH2 terminus.
(B) Expression of the Vav2-DPC, truncation, and point mutants in stably and transiently transfected NIH 3T3 cells.
FIG. 2. Mutation of the Vav2 PH domain decreases Vav2 transforming and signaling activity. (A) NIH 3T3 cells were transfected with the
empty pCGN-hygro plasmid (Vector) or pCGN-hygro plasmids encoding the various PH domain mutants (Fig. 1; 1 g per 60-mm-diameter dish).
The appearance of transformed foci was quantitated on day 14. The values represent the averages 	 standard errors of three dishes and are
representative of at least three independent assays. WT, wild type. (B) NIH 3T3 cells were transiently transfected with the empty pCGN-hygro
plasmid or pCGN-hygro plasmids encoding the various PH domain mutants (100 ng per 60-mm-diameter dish), together with a mutant serum
response element luciferase reporter plasmid to determine stimulation of SRF. Fold activation was determined by the number of relative luciferase
units relative to the number of units seen with the empty vector control. Data are representative of at least three independent assays performed
on duplicate plates.
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Vav2-DPC (Fig. 1A). First, we substituted a leucine for the
invariant tryptophan residue that occurs in all PH domains and
that is essential for the transforming ability of several Dbl
family oncoproteins (30, 40) [designated Vav2-DPC(W503L)].
This mutation is expected to disrupt the global PH fold and
completely abolish PH domain function (22). Second, we in-
troduced mutation K407A, analogous to one introduced into
Vav (K404A), which impairs PIP2 binding and decreases ex-
change activity toward Rac1 in vitro (18).
We evaluated the expression of each mutant protein to de-
termine if these point mutants were altered in protein stability.
First, we assessed the levels of protein expression when Vav2-
DPC and each mutant were expressed in transiently trans-
fected NIH 3T3 cells. Second, we transfected NIH 3T3 cells
with the empty pCGN-hygro mammalian expression vector
and pCGN-hygro encoding Vav2-DPC and the W503L and
K407A mutant proteins to establish mass populations of stably
transfected cells. We detected comparable levels of protein
expression for all mutants in the transiently or stably trans-
fected NIH 3T3 cells, suggesting that the different amino acid
substitutions did not cause a significant alteration in protein
stability (Fig. 1B).
We next performed focus formation transformation assays
with NIH 3T3 cells to evaluate the effect of the PH domain
mutations on Vav2 transforming activity. Surprisingly, we
found that, compared to that of Vav2-DPC, the transforming
activity of the K407A mutant was decreased greater than
threefold whereas the W503L mutant completely lost trans-
forming activity (Fig. 2A). These results contrast with those
made with Vav and Vav3 (26, 28) and demonstrate that a
functional PH domain, within the context of the intact Vav2-
DPC cassette, is required for full Vav2 transforming activity.
We next determined whether mutations in the PH domain
correlated with decreased activation of the SRF signaling path-
way mediated by Rac1, Cdc42, and RhoA activation. NIH 3T3
cells were transiently transfected with expression vectors en-
coding Vav2-DPC and the PH domain mutant proteins. We
found that the decreased transforming potential of the PH
domain mutants correlated directly with a reduced ability to
stimulate SRF activation (Fig. 2B). Vav2-DPC expression
greatly enhanced SRF activity (70-fold), whereas the K407A
mutant exhibited an approximately 10-fold-reduced ability to
stimulate SRF activity and the W503L mutant was completely
inactive.
Vav2 does not require an intact PH domain for the activa-
tion of GTPases in vitro, but a PH domain is required for
facilitating membrane association. Based on observations
from structure-function analyses of other Dbl family proteins,
the PH domain may be critical for the intrinsic catalytic activity
of the DH domain (24, 34, 44) or, alternatively, may regulate
the subcellular location of Vav2 to facilitate DH domain in-
teraction with its membrane-bound GTPase substrates (40,
41). To distinguish between these two possibilities, we next
investigated the guanine nucleotide exchange activity of wild-
type and mutant Vav2-DPC in vitro. For these analyses, we
purified bacterially expressed hexahistidine-tagged versions of
wild-type Vav2-DPC and Vav2-DPC PH domain mutants and
analyzed the activity of these proteins by quantitation of mant-
GDP incorporation into bacterially expressed Rac1, Cdc42,
and RhoA proteins. Although both mutant proteins were ex-
pressed at equivalent levels in E. coli, the W503L mutant
protein was completely insoluble when isolated, thereby pre-
venting any detailed biochemical analysis. Consequently, we
were only able to evaluate the consequences of the K407A
mutant for exchange activity in vitro.
RhoA, Rac1, and Cdc42 alone did not exhibit significant
intrinsic GDP dissociation activity in vitro (Fig. 3). As we
found for Vav2-D and Vav2-DP (1), Vav2-DPC stimulated
rapid GDP dissociation from Rac1, Cdc42, and RhoA, which
was complete within approximately 20 min (Fig. 3). Interest-
ingly, the wild-type and K407A mutant Vav2-DPCs exhibited
identical exchange activities on Rac1 (Fig. 3A). We also found
that the K407A mutant displayed slightly decreased but com-
parable exchange activities toward Cdc42 and RhoA (Fig. 3).
Therefore, mutation of residue K407 which was designed to
eliminate phosphoinositide binding and is necessary for activity
in vivo did not alter the GTPase specificity or catalytic activity
of the Vav2-DPC fragment in vitro.
FIG. 3. Stimulation of mant-GDP incorporation into Rac1, Cdc42,
and RhoA by the Vav2 PH domain mutants in vitro. The abilities of
bacterially expressed wild-type Vav2-DPC and Vav2-DPC PH domain
mutants (50 nM) to stimulate the incorporation of mant-GDP into
bacterially expressed (2 M) Rac1 (A), Cdc42 (B), and RhoA (C) were
measured by fluorescence spectroscopy (ex  360 nm; em  440 nm).
Arrows, time point (300 s) at which the Vav2 PH or CRD polypeptides
were added to the exchange reaction mixture. Results are representa-
tive of two independent assays.
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Since the PH domain has been shown to contribute to the
membrane association of at least some Dbl family proteins (40,
41), we assessed the possibility that mutations in the PH do-
main impaired membrane association. For these analyses, we
performed crude subcellular fractionation (100,000 
 g) with
cell lysates from NIH 3T3 cells stably expressing the wild-type
or mutant Vav2-DPC proteins (Fig. 4). Control Western blot
analyses were done to verify that the fractionations of all cell
lysates were equivalent, and we found that equal amounts of
endogenous RhoGDI were detected only in the cytosolic frac-
tion and that equal amounts of endogenous Ras were detected
only in the membrane-containing fraction (data not shown).
Whereas a significant fraction (approximately 40%) of Vav2-
DPC was found in the P100 membrane-containing fraction, the
two Vav2-DPC PH domain mutants (K407A and W503L mu-
tants) exhibited a significant loss of association with the P100
fraction. In addition, these results support a role for the PH
domain in contributing to Vav2 membrane association. Thus
the loss of transforming activity due to mutation of the PH
domain may be a consequence of impaired DH domain inter-
action with its membrane-bound GTPase substrates in vivo.
Mutation of the CRD disrupts Vav2 signaling and transfor-
mation. Previous studies determined that missense mutations
that completely disrupt the structural integrity of the CRD
result in a complete loss of Vav and Vav3 biological activity
(11, 28). Similarly, we determined that deletion of the CRD
from Vav2-DPC also resulted in a complete loss of transform-
ing and signaling activity (Fig. 2). However, the functional
consequences of these approaches to disrupt CRD function
may be indirect, due to nonspecific disruption of the function
of flanking domains. Furthermore, as we have seen with the
CRD of Raf-1, multiple ligands can interact with the CRD and
have either positive (e.g., Ras) or negative (14-3-3) regulatory
roles 10; J. K. Drugan, G.-S. Yi, J. G. Williams, G. J. Clark,
H. R. Mott, C. J. Der, and S. L. Campbell, submitted for
publication). Thus, a complete disruption of CRD function
may not reveal such a complexity of regulation.
To better characterize the role of the CRD in Vav2-medi-
ated transformation and signaling, we introduced missense
mutations into the CRD of Vav2-DPC at conserved, charged,
surface-exposed regions that are not predicted to affect the
structural integrity of the CRD. These point mutations were
generated based on homology sequence alignments of CRD
sequences for the various Vav family members, Raf-1, and
protein kinase C (PKC) (19); known ligand-binding sequences
of other CRDs; and our previously determined nuclear mag-
netic resonance solution structure of the Raf-1 CRD (Fig. 5)
(27). Structural studies on the Raf-1 CRD revealed binding
determinants in the CRD that selectively interfere with ligand
binding interactions. Based on these analyses, we changed ly-
sines 533 and 538 to alanines [mutants Vav2-DPC(K533A) and
Vav2-DPC(K538), respectively] (Fig. 1A and 5). These resi-
dues in Vav2 correspond to residues L149 and F151 in Raf-1,
which appear to directly contact Ras but not 14-3-3 or phos-
phatidylserine (42). We also mutated lysine 563 to alanine and
valine 568 to glutamic acid [mutants Vav2-DPC(K563A) and
Vav2-DPC(V568E), respectively] (Fig. 1A). These residues
correspond to a region in Raf-1 that, for the most part, has not
been characterized.
Western blot analysis of transiently or stably transfected
NIH 3T3 cells confirmed that the CRD mutations did not
perturb protein stability (Fig. 1B). We then performed focus
formation assays to evaluate the effect of each of the CRD
mutations on Vav2 transforming activity (Fig 6A). We found
FIG. 4. The Vav2 PH domain, but not the CRD, influences sub-
cellular distribution. NIH 3T3 cells were transiently transfected with
the empty pCGN mammalian expression vector and pCGN plasmids
encoding the various PH domain and CRD mutants (Fig. 1; 1 g per
60-mm-diameter dish). Subcellular fractions were prepared 48 h after
transfection by lysis of cells in hypotonic buffer (0.1 M Tris [pH 7.4],
0.5 M MgCl2, 1 mM Pefabloc, 1 M leupeptin, 2 M pepstatin, 0.1%
aprotinin) and addition of NaCl to adjust the ionic strength to 0.15 M,
followed by ultracentrifugation for 30 min at 100,000 
 g as described
previously (5). Proteins in the crude S100 (S) and P100 (P) fractions
were precipitated with 5 ml of acetone for 1 h at 4°C, collected by
centrifugation at 2,000 
 g for 30 min, and resuspended in 100 l of
electrophoresis sample buffer. Equal volumes of each fraction were
separated by sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis, and protein expression was determined by Western blot analysis
using the anti-HA epitope antibody.
FIG. 5. Alignment of representative CRDs. The conserved cysteine and histidine residues in the different Raf serine/threonine kinases and Vav
protein CRDs were aligned. Black shading, identical residues; gray shading, highly conserved residues, dashes, gaps in the alignment with PKC
C1A. Residues in PKC C1A involved in diacylglycerol (DAG) and membrane binding (membrane) are indicated (19). Residues in human c-Raf-1
involved in Ras and 14-3-3 binding are also indicated (19). Arrows, residues that were mutated in human Vav2.
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that, compared to that of the parental Vav2-DPC protein, the
transforming activities of the K533A, K538A, and V568E mu-
tants were impaired significantly (62 to 79% reduction),
whereas the K563A mutant completely lost focus-forming ac-
tivity (Fig. 6A).
We also compared the abilities of the CRD mutants to
stimulate transcriptional activation of SRF. We found that the
degree of stimulation seen with SRF correlated directly with
transforming activity (Fig. 6B). The weakly transforming
K533A, K538A, and V568E mutants showed a weak ability to
stimulate transcription from SRF: levels were two- to threefold
less than the activity seen with the nonmutated Vav2-DPC
protein. The nontransforming K563A mutant showed minimal
ability to activate SRF.
Vav2 requires an intact CRD for the activation of GTPases
in vitro. An intact CRD may be critical for the intrinsic cata-
lytic activity of the DH domain (28) or, alternatively, by anal-
ogy to the CRD of PKC, may regulate subcellular location to
facilitate DH domain interaction with its membrane-bound
GTPase substrates (19). To address these two possibilities, we
evaluated the GEF activity and specificity of bacterially ex-
pressed Vav2-DPC proteins containing the CRD mutations.
We observed two unexpected results from these analyses. First,
although all four CRD mutations compromised GEF activity
in vitro, the degree of impairment was not uniform for all three
Rho GTPases and was most severe for RhoA. For example,
whereas K538A, K563A, and K568E mutants showed a slight
but reproducible decrease in exchange on Rac and Cdc42 (Fig.
7A and B), all three were severely compromised in their ability
to mediate exchange on RhoA (Fig. 7C). Substitution of K533,
a residue in the region that corresponds to the phorbol ester
binding site of PKC, caused the most-severe reductions in
exchange activity toward all three GTPases. Vav2-DPC har-
boring this substitution retained a small amount of activity
toward Rac1 and Cdc42 but was almost completely inactive on
RhoA (Fig. 7). Second, the degree of impairment in GEF
activity in vitro did not correlate directly with the impairment
in signaling and transforming activity. Although K563E caused
the most drastic reduction in transforming activity, it was the
K533A mutant that was the most impaired in GEF activity.
These results indicate that the CRD is critical for regulating
the intrinsic catalytic activity of the DH domain, most critically
for RhoA, and the consequences of the CRD mutations for
transforming activity cannot be ascribed solely to perturbation
of the intrinsic guanine nucleotide exchange activity.
CRDs have been shown to promote the membrane associa-
tion of PKC and other signaling proteins (19). Therefore, we
assessed the possibility that mutations in the CRD may also
impair Vav2-DPC activity as a consequence of impaired mem-
brane association. In contrast to our observations with the PH
domain mutants, which were largely cytosolic (95%), the
Vav2 CRD K533A, K538A, and V568E mutants exhibited only
slight reductions in the amount of protein in the membrane-
containing fraction (30 to 40% in P100) compared to Vav2-
DPC (Fig. 4). However, Vav2-DPC(K563A) had a significantly
decreased amount of protein in the P100 fraction (20% of total
protein). Thus, these results support a role for the CRD in
contributing to Vav2 membrane association and suggest that
the impaired transforming activity of the K563A mutant is due,
in part, to impaired intrinsic catalytic activity as well as im-
paired interaction with membranes in vivo
PI3K activation enhances Vav2 activity via the PH domain.
Our mutational analyses showed that the PH domain regulates
DH domain activity in vivo but not in vitro. Based on the
observations made with the PH domain of Vav and other Dbl
family proteins, one possible role of the Vav2 PH domain may
be to bind products of PI3K that in turn facilitate Vav2 acti-
vation (18). To determine if PI3K products are regulators of
Vav2 activity, we tested whether coexpression of activated
PI3K would cooperate with Vav2-DPC to cause enhanced sig-
FIG. 6. Mutation of the Vav2 CRD decreases Vav2 transforming and signaling activity. (A) NIH 3T3 cells were transfected with the empty
pCGN-hygro plasmid or pCGN-hygro plasmids encoding the various CRD mutants (Fig. 1; 1 g per 60-mm-diameter dish). The appearance of
transformed foci was quantitated on day 14. The values represent the averages 	 standard errors of three dishes and are representative of at least
three independent assays. WT, wild type. (B) NIH 3T3 cells were transiently transfected with empty pCGN plasmid or pCGN plasmids encoding
the various CRD mutants (100 ng per 60-mm-diameter dish), together with the SRF luciferase reporter plasmid. Fold activation was determined
by the number of relative luciferase units relative to the number of units seen with the empty vector control. Data are representative of at least
three independent assays performed on duplicate plates.
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naling and focus-forming activity. NIH 3T3 cells were trans-
fected with the expression vector encoding Vav2-DPC, either
alone or with an expression vector encoding a plasma mem-
brane-targeted and constitutively activated variant of the p110
catalytic subunit of PI3K (p110-CAAX) (33). Expression of
p110-CAAX alone did not result in any focus formation,
whereas Vav2-DPC alone caused the appearance of 67 foci per
dish; coexpression of p110-CAAX caused a twofold synergistic
enhancement of this activity (Fig. 8A). Activated PI3K alone
did not activate SRF and also caused a similar twofold en-
hancement of Vav2-DPC stimulation of SRF (Fig. 8B). These
results suggest that products of PI3K appear to stimulate
Vav2-DPC activity in vivo. Finally, to verify that p110-CAAX
was active, we monitored the phosphorylation state of a PI3K
target, Akt/protein kinase B, using phosphospecific Akt anti-
bodies (Fig. 8C). Expression of p110-CAAX caused an in-
crease in Akt phosphorylation. Interestingly, Vav2-DPC also
caused Akt phosphorylation, which was enhanced by coexpres-
sion of p110-CAAX.
The ability of PI3K activation to cooperate with Vav2-DPC
may result from the cooperation of two independent signaling
pathways or, alternatively, may be due to direct enhancement
of Vav2-DPC catalytic function. We found that coexpression of
p110-CAAX with Vav2 caused an enhanced formation of
GTP-bound Rac1, suggesting that PI3K activation may result
in enhanced Vav2 DH domain catalytic activity in vivo (Fig.
9A). We then determined whether the enhanced exchange
activity was facilitated by the increased association of Vav2-
DPC with membranes. However, fractionation analyses
showed that coexpression of p110-CAAX did not increase the
fraction of Vav2-DPC associated with the membrane fraction
(Fig. 9B). Thus, PI3K stimulation of Vav2 DH domain activity
may be due to modulation of the intrinsic catalytic function of
the DH domain.
Finally, we determined if the ability of PI3K activity to mod-
ulate Vav2-DPC activity is dependent on the PH domain or the
CRD. We found that coexpression of p110-CAAX did not
enhance the signaling or transforming activity of either PH
domain mutant, indicating that an intact PH domain was im-
portant for PI3K to modulate Vav2 function (Fig. 8A and B).
The inability of PI3K to stimulate the activity of the K407A
mutant is also consistent with previous studies demonstrating
the importance of this residue in the PH domain of Vav for
binding to PIP3 in vitro (18). In contrast, we found that the
transforming and signaling activities of the K533A, K538A,
and K563A mutants retained responsiveness to activated PI3K
to a limited degree (Fig. 7A and B). Thus, PI3K stimulation of
Vav2-DPC appears to be dependent on an intact PH domain
but not CRD.
DISCUSSION
The tandem DH/PH domain structure of all Dbl family
proteins suggests that the PH domain is a critical regulator of
DH domain catalytic activity (8, 39). Consistent with such a
role, the PH domain has been found to be a critical positive
regulator of DH domain function for the majority of Dbl fam-
ily proteins. In contrast, the PH domains of Vav and Vav3 were
found to be dispensable for DH domain activity. Instead, a
CRD adjacent to the PH domain was demonstrated to be
essential for Vav DH domain function in vitro and in vivo (11,
28), suggesting that the CRD may substitute for PH domain
function. In the present study, we evaluated the role of the PH
domain and CRD in regulating the function of the DH domain
of Vav2. Unexpectedly, we found that the PH domain was
critical for Vav2 signaling and transformation. An intact PH
domain was dispensable for the intrinsic catalytic activity of the
DH domain in vitro and, instead, facilitated Vav2 membrane
association. We found that missense mutations in the CRD
abolished or impaired Vav2 transforming and signaling activ-
ity. We also found that all mutations of the CRD impaired
catalytic activity in vitro. However, the lack of a direct corre-
lation between impaired transforming activity and impaired
catalytic activity in vitro argues that the CRD must facilitate
DH domain function by other means, including regulation of
membrane association. Finally, we found that PI3K activation
synergistically enhanced Vav2 transforming and signaling ac-
FIG. 7. Stimulation of mant-GDP incorporation into Rac1, Cdc42,
and RhoA by the Vav2 CRD mutants in vitro. The ability of bacterially
expressed wild-type (WT) Vav2-DPC (50 nM) and Vav2-DPC with the
listed substitutions within the CRD (50 nM) to stimulate the incorpo-
ration of mant-GDP into bacterially expressed (2 M) Rac1 (A),
Cdc42 (B), and RhoA (C) was measured by fluorescence spectroscopy
(ex  360 nm; em  440 nm). Arrows, time point (300 s) at which the
Vav2 CRD polypeptides were added to the exchange reaction mixture.
Results are representative of two independent assays.
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tivity by stimulating a PH domain-dependent increase in the
intrinsic catalytic activity of the DH domain that did not in-
volve promotion of membrane association. We conclude that
the PH domain and CRD serve distinct but positive regulatory
roles in Vav2 DH domain function.
Previous mutagenesis studies evaluated the importance of
the PH domain in Vav and Vav3 function and concluded that
the PH domain served either a negative regulatory, or dispens-
able, role in Vav DH domain function. For example, Ma et al.
found that deletion of the PH domain in full-length Vav re-
sulted in a constitutively activated variant (26). Movilla and
Bustelo observed that mutation of the invariant tryptophan
residue in the PH domain of Vav3, in the context of the
isolated DH/PH/CRD fragment, did not alter exchange activity
in vitro or biological activity in NIH 3T3 cells (28). Thus, we
were surprised to find that introduction of missense mutations
in the PH domain impaired or abolished Vav2-DPC signaling
and transforming activity. Why do our observations differ from
those of other studies? One possibility is that the PH domain
may have functions in Vav2 distinct from those in Vav and
Vav3. The PH domain is one of the less conserved domains
among Vav family proteins (6). However, we have also found
that mutation of the PH domain of Vav, in the context of the
DH/PH/CRD fragment, also abolishes signaling and trans-
forming activity (T. Palmby, K. Abe, and C. J. Der, submitted
for publication). Therefore, in our analyses, the PH domain
has equivalent and necessary roles in the functions of two Vav
family proteins. Thus, at present, we do not have a straight-
forward explanation for the different observations. Neverthe-
less, our conclusion that the PH domain serves a positive
regulatory role in Vav2 DH domain function is similar to
observations made for other Dbl family proteins. Finally, we
should also stress that our studies evaluated PH domain func-
tion in a truncated, constitutively activated Vav2 protein vari-
ant. Whether the PH domain also serves a positive regulatory
role in the full-length protein remains unresolved.
Structure-function analyses of other Dbl family proteins es-
tablished two possible roles for the PH domain in regulating
DH domain function. First, a comparison of the catalytic ac-
tivities of the isolated DH and DH/PH domains of several Dbl
family proteins (Dbl, Trio, and Dbs) found that the presence of
the PH domain caused up to a 100-fold-enhanced guanine
nucleotide exchange activity in vitro (24, 34, 44). However, we
found that the K407A mutation in the PH domain did not
significantly perturb catalytic activity in vitro. While we were
FIG. 8. Coexpression of activated PI3K causes enhancement of the transforming and signaling activities of Vav2 DPC but has minimal effect
on the Vav2 PH or CRD mutants. Assays were performed as described in the legends for Fig. 2 and 5 except that 500 ng of the pZIP-NeoSV(x)1
empty vector (black bars) or pZIP-NeoSV(x)1 encoding activated PI3K (p110-CAAX) (open bars) was cotransfected with 100 ng of pCGN-hygro
plasmid DNA encoding the indicated Vav2 protein. (A) NIH 3T3 cells were cotransfected with control plasmid pCGN-hygro (vector) encoding
the indicated Vav2 PH domain mutant proteins (Fig. 1; 100 ng per 60-mm-diameter dish), together with pZIP-NeoSV(x)1 (vector) or pZIP-p110-
CAAX (500 ng per 60-mm-diameter dish). Values are the averages 	 standard errors for two dishes and are representative of three independent
assays. WT, wild type. (B) NIH 3T3 cells were transiently transfected with the above plasmids along with a luciferase reporter construct for SRF
transcriptional activity. Data are representative of at least three independent assays performed on duplicate plates. (C) The expression of
p110-CAAX in the SRF reporter assay (B) was analyzed by Western blotting 20 g of total cell lysates with an anti-Akt and an anti-phospho-Akt
(P-Akt) antibody.
FIG. 9. Coexpression of activated PI3K and Vav2-DPC caused a
synergistic increase in the level of Rac1-GTP but did not increase
Vav2-DPC membrane association. (A) NIH 3T3 cells stably expressing
Vav2-DPC, p110CAAX, or both were cultured for 24 h in low serum
(0.1%) and lysed, and the lysates were used in GST pull-down assays
using GST-PAK Rac binding domain (RBD) immobilized on glutathi-
one agarose beads. Bound proteins and total cell lysates were analyzed
by Western blotting with anti-Rac1 antibodies. The expression of
Vav2-DPC was analyzed by Western blotting total cell lysates with an
anti-HA antibody. The expression of p110-CAAX was analyzed by
Western blotting total cell lysates with an anti-phospho-Akt antibody
(data not shown). (B) PI3K activation does not enhance Vav2-DPC
association with membranes. NIH 3T3 cells were cotransfected with
the control plasmid pCGN (vector) encoding Vav2-DPC (1 g per
60-mm-diameter dish), together with pZIP-NeoSV(x)1 (vector) or
pZIP-p110CAAX (500 ng per 60-mm-diameter dish). Subcellular frac-
tionation was performed as described for Fig. 4.
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unable to evaluate this issue with the more drastic W503L
mutation, which is expected to completely perturb PH domain
structure, Movilla and Bustelo found that the equivalent mu-
tation in the PH domain of Vav3 also did not impair catalytic
activity in vitro (28). Thus, in contrast to results of observations
for other Dbl family proteins (24, 34, 44), the PH domain does
not greatly influence the intrinsic catalytic activity of the DH
domain. Finally, the PH domains of some Dbl family proteins
were observed to be critical for protein function yet could be
replaced by a plasma membrane-targeting sequence (40, 41).
Our observation that the two PH domain mutations greatly
impaired Vav2-DPC association with the membrane fraction is
consistent with a role for the PH domain in promoting DH
domain interaction and activation of its membrane-associated
GTPase substrates. In support for such a role, we found that
addition of a membrane-targeting sequence partially restored
the transforming activity of the K407A mutant version of Vav
(Palmby et al., submitted). However, addition of a membrane-
targeting sequence to the more drastic W503L version of Vav
did not restore the ability of this mutant Vav to transform NIH
3T3 cells or activate SRF. Thus, the PH domains of Vav pro-
teins must serve a function independent of membrane target-
ing.
Previous studies showed that deletion of the CRD or intro-
duction of missense mutations that disrupt the structural in-
tegrity of this domain eliminated the transforming activity of
Vav and Vav3 in vivo and in vitro (11, 28). Consistent with
these studies, we have shown that truncation of the CRD also
completely eliminates the biological activity of the Vav2-DPC
cassette. While these analyses clearly demonstrate the critical
role of the CRD for the function of all Vav family proteins,
they do not provide much insight into what that role may be.
Similar to the CRD of the Raf-1 serine/threonine kinase, the
CRDs of Vav family proteins are atypical in that they do not
bind diacylglycerol or phorbol esters and instead may bind
small GTPases and other membrane lipids. However, we and
others have shown that the Raf-1 CRD interacts with multiple,
distinct ligands that regulate Raf-1 kinase activity (4, 13, 15, 16,
25, 42). Therefore, we further investigated the functional con-
tributions of the Vav2 CRD by introducing specific missense
mutations at surface-exposed residues not predicted to disrupt
the global fold of the CRD. These mutations were based on
our previously determined nuclear magnetic resonance solu-
tion structure of the CRD of Raf-1 and on mutagenesis anal-
yses of the CRD of PKC and Raf-1 (27, 32, 36). These mutants
all decreased Vav2 transforming and signaling activity to var-
ious degrees. Interestingly, the impairment in catalytic ex-
change activity for these mutants did not correlate directly with
the impairment in biological activity. In particular, the K533A
mutant was significantly reduced in its catalytic activity toward
Rac, Cdc42, and RhoA in vitro, while the K538A and V568E
mutants showed decreased activity toward RhoA alone. De-
spite this difference, all three showed comparable, modest re-
ductions in transforming activity. Thus, while our results indi-
cate that the Vav2 CRD is involved in mediating DH domain
catalytic activity, by analogy to the CRD of Raf-1, we also
suggest that the Vav2 CRD may also facilitate interaction with
other molecules that can influence DH domain function in
vivo.
Movilla and Bustelo observed that the CRD of Vav3 could
bind to its GTPase substrates in vitro and suggested that the
CRD may facilitate DH domain interaction with its substrates
(28). Our observation that mutation of the CRD impaired
Vav2 catalytic activities in vitro is also consistent with this
observation. Therefore, experiments to determine if the Vav2
CRD mutants are deficient in substrate binding would help
elucidate the exact residues that may be important for specific
GTPase recognition or other protein ligands that are required
for complete catalytic activation.
Another possible role for the CRD of Vav2 may be to serve
as a lipid binding, membrane-targeting sequence. The tandem
CRDs from various PKC isoforms have been shown to pro-
mote translocation to the plasma membrane upon interaction
with diacylglycerol and phorbol ester (19). Although the CRD
of Vav2 does not bind phorbol esters, it may function to target
Vav2 to the plasma membrane by interacting with membrane-
associated phospholipids or other protein ligands. However,
specific mutations in the CRD (K533A, K538A, and V568E)
that impaired Vav2 function did not cause a significant alter-
ation in membrane association. Furthermore, we found that
the loss of function due to mutation of the CRD of Vav could
not be corrected by addition of a plasma membrane-targeting
sequence (Palmby et al., submitted). Thus, it seems unlikely
that the CRD facilitates the membrane association of Vav or
Vav2. Studies to determine if the CRD mutants can interact
with the 14-3-3 adapter protein or with other cellular proteins
would help determine whether the CRD serves as a protein
interaction domain, analogous to the Raf-1 kinase.
Finally, previous studies suggest that the products of PI3K,
such as PIP3, can associate with the PH domains of Vav and
Sos to promote the activation of these Dbl family proteins in
vitro and in vivo (18, 29). Our in vitro exchange analyses
showed that the K407A PH domain mutant, which is expected
to be impaired in phosphoinositide binding, retained strong
catalytic activity. Thus, we anticipated that products of PI3K
would not enhance Vav2 activity in vivo. However, we found
that PI3K activation synergistically stimulated Vav2 transform-
ing and signaling activity. Since expression of PI3K with Vav2
resulted in enhanced formation of GTP-bound Rac1, this in-
dicates that PI3K products may enhance the intrinsic catalytic
activity of the DH domain in vivo. Thus, our results are con-
sistent with the observations of Han and colleagues, who pro-
pose that PIP3 association with the PH domain enhances the
intrinsic catalytic activity of the DH domain of Vav (18).
Interestingly, the PI3K modulation of biological activity was
independent of membrane association, as our fractionation
analyses showed no difference in subcellular localization of the
Vav2-DPC fragment in the presence of a constitutively acti-
vated PI3K. According to previous studies (21), in order to
promote a PI3K-mediated membrane targeting event, PI3K
products must exhibit high-affinity binding and have at least a
25-fold-higher affinity for PIP3 than for PIP2 for a PH domain
to function as a PI3K-stimulated membrane-targeting domain,
such as the PH domain of Akt. Therefore, our observation that
PI3K activation enhanced Vav2 activity in vivo independent of
promoting plasma membrane association was not surprising.
Our observations argue that the PH domain will only facilitate
membrane association by cooperating with other membrane-
targeting domains. This mechanism is illustrated by findings
that efficient recruitment of the -adrenergic receptor kinase
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(ARK) to membranes requires the cooperative binding of the
COOH terminus of ARK to G subunits and of the PH
domain of ARK to PIP2 (31). Additionally, we found that,
unlike the PH domain of the Akt serine/threonine kinase, the
isolated PH domain of Vav did not show PI3K activation-
mediated association with the plasma membrane (T. Palmby
and C. J. Der, unpublished data). Thus, Vav2 catalytic activity
and function, but not subcellular location, appear to be posi-
tively modulated by activation of PI3K, and this enhanced
activity requires intact CRD and PH domains.
In summary, our observations show that, unlike other Dbl
family members, Vav2 requires both a PH domain and a CRD
in addition to its catalytic DH domain to transform NIH 3T3
cells. Our studies further demonstrate that PI3K lipid second
messengers synergistically enhance Vav2 transforming and sig-
naling activity in the context of Vav2-DPC but have no effect
on polypeptides harboring missense mutations in either the PH
domain or the CRD. Finally, these analyses suggest the both
the PH domain and the CRD contribute a second essential
function independent of membrane association in order to
facilitate guanine exchange activity of the DH domain and that
this function may encompass binding to other protein or lipid
ligands.
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